Reversing Liver Fibrosis: A Combination of Anti-NASH siRNA & Semaglutide

Time: 11:00 am
day: Day 2 Seminar A Pre-Lunch Tracks


  • Identifying genomic variants from a large group of patients to derive robust targets
  • Delving into the effects of weight loss to due to energy expenditure compared to incretin-based drugs
  • Disentangling the forthcoming combination studies to increase the efficacy of reversing liver fibrosis and inducing reduction of liver fat content